Sangamo Therapeutics (FRA:GBY) EBITDA Margin %: -2,155.17% (As of Mar. 2026)

Author:

Vera Yuan

Director of Data and Quant Analytics at GuruFocus

Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.

View Profile →

Reviewed by:

Charlie Tian

Founder & CEO of GuruFocus

Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

View Profile →

What is Sangamo Therapeutics EBITDA Margin %?

Sangamo Therapeutics FRA:GBY EBITDA Margin % is -2,155.17% as of Mar. 2026. The stock has 6 warning signs investors should review. Among 940 Biotechnology companies, Sangamo Therapeutics ranks worse than 66.38% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Sangamo Therapeutics's EBITDA for the three months ended in Mar. 2026 was €-26.88 Mil. Sangamo Therapeutics's Revenue for the three months ended in Mar. 2026 was €1.25 Mil. Therefore, Sangamo Therapeutics's EBITDA margin for the quarter that ended in Mar. 2026 was -2,155.17%.

Sangamo Therapeutics (FRA:GBY) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Sangamo Therapeutics EBITDA Margin % Related Terms

Sangamo Therapeutics EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Sangamo Therapeutics's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sangamo Therapeutics EBITDA Margin % Chart

Sangamo Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

EBITDA Margin %

Get a 7-Day Free Trial

-149.68

-162.37

-54.93

-154.13

-253.85

Sangamo Therapeutics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
EBITDA Margin %	Get a 7-Day Free Trial															-430.40	-87.18	-5,792.73	-162.25	-2,155.17

FRA:GBY vs LSTA, LITS, NNVC: EBITDA Margin % Comparison

For the Biotechnology subindustry, Sangamo Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sangamo Therapeutics EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sangamo Therapeutics's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Sangamo Therapeutics's EBITDA Margin % falls into.

Save Embed

Sangamo Therapeutics EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Sangamo Therapeutics's EBITDA Margin % for the fiscal year that ended in Dec. 2025 is calculated as

EBITDA Margin %	=	EBITDA (A: Dec. 2025 )	/	Revenue (A: Dec. 2025 )
	=	-85.743	/	33.777
	=	-253.85 %

Sangamo Therapeutics's EBITDA Margin % for the quarter that ended in Mar. 2026 is calculated as

EBITDA Margin %	=	EBITDA (Q: Mar. 2026 )	/	Revenue (Q: Mar. 2026 )
	=	-26.875	/	1.247
	=	-2,155.17 %

Frequently Asked Questions Learn more about EBITDA Margin % →

What does a EBITDA Margin % of -2,155.17% mean?

Sangamo Therapeutics (FRA:GBY) has a EBITDA Margin % of -2,155.17% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Sangamo Therapeutics and its competitors. According to the industry distribution chart, Sangamo Therapeutics ranks #624 out of 940 companies in the Biotechnology industry, placing it in the top 66.4%.

Is Sangamo Therapeutics' EBITDA Margin % too high?

Sangamo Therapeutics' current EBITDA Margin % is -2,155.17%. Based on the distribution chart, Sangamo Therapeutics ranks #624 out of 940 companies in the Biotechnology industry, which is below the industry midpoint.

How does Sangamo Therapeutics' EBITDA Margin % compare to LSTA and LITS?

According to the Biotechnology industry distribution chart, Sangamo Therapeutics ranks #624 out of 940 companies for EBITDA Margin %. This places Sangamo Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EBITDA Margin % for a Biotechnology company?

A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EBITDA Margin % mean?

A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Sangamo Therapeutics and its competitors. Sangamo Therapeutics's current EBITDA Margin % is -2,155.17%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Sangamo Therapeutics stock overvalued right now?

Sangamo Therapeutics (FRA:GBY) has a current EBITDA Margin % of -2,155.17%. The stock's GF Value™ is €0.18, compared to a current price of €0.07 — trading 63.2% below its estimated fair value. The current EBITDA Margin % is -2,155.17%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EBITDA Margin % calculated?

EBITDA Margin % is calculated from a company's financial statements. For Sangamo Therapeutics (FRA:GBY), the current EBITDA Margin % is -2,155.17% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sangamo Therapeutics Business Description

Industry Healthcare Biotechnology

Comparable Companies LSTA LITS NNVC ATNM DARE DYAI GRDX TVGN KYNB PSTV VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges SGMO:USA 0R1D:UK GBY:Germany

Address 501 Canal Boulevard, Richmond, CA, USA, 94804

Website https://www.sangamo.com

Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its neurology development is focused on two areas: development of epigenetic regulation therapies to treat serious neurological diseases and development of novel engineered adeno-associated virus, or AAV, capsids to deliver its therapies to the intended neurological targets. The group's pipeline products are Small Fiber Neuropathy, Prion Disease, Tauopathies, ALS/FTD, Huntington's Disease, Fabry Disease, and Hemophilia A.